Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$22.39 - $38.94 $783,650 - $1.36 Million
35,000 New
35,000 $988,000
Q1 2022

May 13, 2022

SELL
$30.13 - $50.0 $506,907 - $841,200
-16,824 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$22.28 - $39.54 $374,838 - $665,220
16,824 New
16,824 $665,000

Others Institutions Holding RXDX

About Prometheus Biosciences, Inc.


  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Long Focus Capital Management, LLC Portfolio

Follow Long Focus Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Long Focus Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Long Focus Capital Management, LLC with notifications on news.